| 04.28.22 | Lilly obesity drug clears high bar set by N ovo’s Wegovy; Pfizer DMD gen e therapy freed from FDA hold

Laden...

2 jaren geleden

Html
Tekst

Today's Rundown

SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity Pfizer's phase 3 DMD gene therapy test resumes after FDA hold, but decision on advanced patients still pending Sio Gene Therapies warns of 'significant' layoffs after ditching final two assets Sponsored: Using Knowledge Graphs to Drive Drug Discovery After Amgen deal, Plexium maintains momentum with AbbVie neurological partnership GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets Lipids that wind down inflammation could be a critical therapeutic tool for MS BioMarin posts record quarterly sales as Voxzogo launch heats up Amgen vows to fight $7.1B tax bill tied to Puerto Rico manufacturing unit Sanofi's Dupixent puts on another stellar show, and it's still 'at the beginning' of the journey: exec

Trending Topic: Cell & Gene Therapy
Read on to understand how the industry is addressing gene therapy and cell therapy research and development.

Featured Story

SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity

By Nick Paul Taylor

The unstoppable march of Eli Lilly’s tirzepatide continues. Having previously shown the dual GIP/GLP-1 agonist reduces the weight of people with diabetes, Lilly has now delivered a hit in its first phase 3 pure play obesity trial, putting Novo Nordisk’s Wegovy on notice that a serious challenger may be on the horizon.

Harness the power of eCOA in your next trial

Keep patients at the center of care while increasing efficiencies, data integrity and regulatory compliance. IQVIA’s leaders will help you deploy strategic eCOA tools, maximize patient needs and acquire real-time insights that demonstrate results. Learn more.

Pfizer's phase 3 DMD gene therapy test resumes after FDA hold, but decision on advanced patients still pending

By Annalee Armstrong

Pfizer is getting back to work on a late-stage test for its Duchenne muscular dystrophy gene therapy. The decision comes several months after a patient death in a phase 1 trial drew a clinical hold on the medicine from the FDA.

Sio Gene Therapies warns of 'significant' layoffs after ditching final two assets

By Max Bayer

Sio Gene Therapies is now without a product after ending clinical development of its last two assets, prompting the company to seek an emergency exit and warn of impending layoffs.

Riding high after an Amgen partnership and a $102 million funding round so far this year, Plexium shows no signs of slowing down. Instead, it's inked a new agreement with AbbVie focused on neurological conditions.

GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets

By Nick Paul Taylor

GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic.

Lipids that wind down inflammation could be a critical therapeutic tool for MS

By Max Bayer

New research from an international team of scientists found that a specific kind of lipid associated with winding down the inflammation could be a boost in treating multiple sclerosis. A new study found administering the lipid reduced pro-inflammatory proteins and immune cells.

BioMarin posts record quarterly sales as Voxzogo launch heats up

By Fraiser Kansteiner

BioMarin tallied record quarterly revenues of $519 million in the first three months of 2022, with new achondroplasia med Voxzogo chipping in $20 million.

Amgen vows to fight $7.1B tax bill tied to Puerto Rico manufacturing unit

By Zoey Becker

When Amgen released first-quarter results on Wednesday, its sales and profit numbers were again overshadowed by a bombshell tax disclosure.

Sanofi's Dupixent puts on another stellar show, and it's still 'at the beginning' of the journey: exec

By Angus Liu

Five years after its first FDA approval in eczema, Sanofi's Dupixent is still blazing a trail in inflammatory diseases. That's the evaluation of Sanofi's global head of specialty care after the drug's sales shot up 46% in the first quarter of 2022.